Search Results
10
Everything
Search Filters
Organization
Y-mAbs Therapeutics, Inc.
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
March 04, 2025 06:35 ET
|
Y-mAbs Therapeutics, Inc.
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
March 03, 2025 07:30 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
February 20, 2025 16:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
February 06, 2025 07:30 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
January 31, 2025 07:35 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
January 10, 2025 09:26 ET
|
Y-mAbs Therapeutics, Inc.
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
January 10, 2025 07:35 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Provides Strategic Business Update and 2025 Priorities
January 10, 2025 07:05 ET
|
Y-mAbs Therapeutics, Inc.
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024 07:30 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
December 07, 2024 12:00 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...